Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (7): 1300-1304.doi: 10.3969/j.issn.1673-8225.2011.07.036

Previous Articles     Next Articles

Combination of basic fibroblast growth factor and insulin for treatment of pressure sore wounds: A randomized controlled study

Huang Su-bi1, Yi Qiang-ying2, Zhang Jie-min1, Du Li1, Zhao Hui1, Lin Ying1   

  1. 1Department of Orthopedics, Nanchong Central Hospital, Nanchong  637000, Sichuan Province, China
    2School of Engineering and Materials Science, Queen Mary, University of London, London E1 4NS, UK
  • Received:2010-11-22 Revised:2010-12-24 Online:2011-02-12 Published:2011-02-12
  • About author:Huang Su-bi, Associate chief nurse, Department of Orthopedics, Nanchong Central Hospital, Nanchong 637000, Sichuan Province, China hsb556@163.com

Abstract:

BACKGROUND: Long-term bed results in pressure sore. How to promote the wound healing and shorten the healing time are the essential parts of pressure sore treatment.
OBJECTIVE: To observe the influence of insulin on the treatment of pressure score wounds using bovine basic fibroblast growth factors.
METHODS: The 34 patients (45 pressure sores) of Sichuan Nanchong Central Hospital were divided into the experimental group and control group. In the control group, all the pressure sore wounds were external applied with wet pledget containing basic fibroblast growth factor (1-3 mL) and physiological saline (3-5 mL) after treated with TDP physiotherapy, while the experimental group was treated with the same process except the addition of insulin. The significant condition and wound healing time were recorded in two groups after 2 weeks, and the results were contrastive analyzed.
RESULTS AND CONCLUSION: Efficiency of experimental group was greater than the control group obviously (P < 0.05). But there was no significant difference between two groups in blood glucose concentration before treatment (P > 0.05). The addition of insulin can promote the healing of pressure sores, without the change of blood glucose levels of patients.

CLC Number: